LGALS3 and hepatocellular carcinoma: In addition, analysis of the transcriptomics data and matched survival data of TCGA HCC patients from UCSD Xena with the median expressions of galectin-3, HK2, and PKM as cutoffs revealed that the survival of the patients with a combined high expression of galectin-3 and HK2 or galectin-3 and PKM was significantly worse than the patients with a combined low expression of galectin-3 and HK2 or galectin-3 and PKM (Fig. 7e).